Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

Fighting Cancer One Patient at a Time

(Forbes) Nov 21, 2017 - Companies large and small are competing to attack rare genetic mutations that cause cancer. The reason? Great science and high drug prices. The result? Soaring stock prices.

read article

Roche, AbbVie Leukemia Drug Superior To Older Medicine In Study

(Reuters) Nov 21, 2017 - Patients with a type of leukemia that had relapsed who received the new drug Venclexta in combination with Rituxan went significantly longer without the disease worsening than those treated with Rituxan and Treanda, according to interim results from a pivotal late stage study released on Tuesday.

read article

Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients

(AbbVie) Nov 21, 2017 - AbbVie today announced that the American Society of Hematology (ASH) has accepted data from the Phase 3 MURANO study evaluating venetoclax tablets in combination with rituximab in patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as an oral, late-breaking presentation during the upcoming 59th ASH Annual Meeting & Exposition, December 9-12, in Atlanta, GA. The abstract is one of six late-breaking abstracts accepted for presentation at the meeting.

read corporate press release

New Gene Treatment Effective For Some Leukemia Patients

(New York Times) Nov 20, 2017 - A new way of genetically altering a patient’s cells to fight cancer has helped desperately ill people with leukemia when every other treatment had failed, researchers reported on Monday in the journal Nature Medicine.

read article

Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes

(StreetInsider) Nov 20, 2017 - Geron Corporation today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of imetelstat in transfusion dependent patients with Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are refractory or resistant to treatment with an erythropoiesis stimulating agent (ESA).

read article

Cancer Immunotherapy Company Tries To Explain Deaths In Recent Trial

(Science Magazine) Nov 16, 2017 - Juno Therapeutics says it is now using insights from its analysis of the fatal events that took place in the ROCKET trial to inform work on a modified cell treatment that is in early-stage clinical trials.

read article

Seattle Children’s Opens First CAR T-Cell Immunotherapy Trial in the U.S. for Children and Young Adults With Leukemia That Targets CD22 and CD19 Proteins Simultaneously

(Seattle Children’s Hospital) Nov 16, 2017 - By launching a bilateral attack on cancer cells, researchers hope to ultimately increase patients’ long-term remission.

read press release

Researchers Discover An Achilles Heel In A Lethal Leukemia

(St. Jude Children’s) Nov 16, 2017 - Scientists led by St. Jude Children’s Research Hospital investigators have uncovered a mechanism of drug resistance in acute myeloid leukemia that offers potential treatments to overcome resistance in other cancers.

read press release

Sandoz Says New Clinical Data Support Two Biosimilars

(Reuters) Nov 14, 2017 - Novartis’ generics division, Sandoz, said new immunology data from four clinical studies supported its proposed biosimilars adalimumab for treating psoriasis and cancer drug rituximab.

read article

Juno Dissects ROCKET Deaths, Will Aim Better CAR-T at Leukemia

(Xconomy Seattle) Nov 10, 2017 — When five patients with a difficult type of leukemia died last year in a clinical trial run by Juno Therapeutics, it was a big setback for the Seattle biotech and its plans for cutting-edge CAR-T cancer therapy. A year later, Juno is finally explaining what happened and promising to return with a new product.

read article

Here’s Why Investors In Geron, Puma Bio, Intrexon, And Ziopharm Should Worry

(STAT Plus/Adam’s Take) Nov 13, 2017 - I’ve been writing too many positive stories lately. They’re ruining my reputation as the Night King of Biotech. This column is a return to normalcy.

read article (paid subscription required)

U.S. Food and Drug Administration Expands Approval of Sprycel® (dasatinib) to Include Treatment of Children with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

(BMS) Nov 10, 2017 - Bristol-Myers Squibb Company today announced the U.S. Food and Drug Administration (FDA) has expanded the indication for Sprycel ® (dasatinib) tablets to include the treatment of children with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).

read corporate press release

Fat Cells May Inactivate Chemotherapeutic Drug

(AACR) Nov 8, 2017 - Adipocytes, or fat cells, can absorb and metabolize the chemotherapeutic agent daunorubicin, reducing the effectiveness of the drug and potentially contributing to poorer treatment outcomes, according to a study published in Molecular Cancer Research, a journal of the American Association for Cancer Research.

read press release

Scientific Study Finds No Link Between Cancer, Monsanto Weedkiller Glyphosate

(The Street) Nov 9, 2017 - The main ingredient in Monsanto's popular herbicide RoundUp has no firm link to cancer, according to a long-term study published in the Journal of the National Cancer Institute.

read article

Cancer Care That Knows No Boundaries: NCCN Guidelines Customized For Use In Africa

(RPCI) Nov 8, 2017 - A new collaborative international effort to improve cancer care in many African nations was launched today with the debut of the NCCN Harmonized Guidelines™ for Sub-Saharan Africa.

read article

FDA Lifts Clinical Hold on Cellectis Phase 1 Clinical Trials with UCART123 in AML and BPDCN

(MarketWatch) Nov 6, 2017 - Cellectis a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), today announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold, previously announced on September 4, 2017, on Phase 1 trials of Cellectis’ UCART123 product candidate in acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN).

read article

FDA Lifts Hold on Cellectis’s “Off the Shelf” CAR-T, With Caveats

(Xconomy New York) Nov 7, 2017 - The FDA has cleared Cellectis to resume testing an experimental “off the shelf” type of cell therapy, so long as it follows a new set of measures meant to quell the safety concerns that caused the company to halt a pair of clinical trials.

read article

Speedy Review For Jazz’ High-Risk AML Chemo

(PharmaTimes [UK]) Nov 6, 2017 - Dublin, Ireland-based Jazz Pharmaceuticals’ Vyxeos is being given a speedy review in Europe as a treatment for certain types of high-risk acute myeloid leukemia (AML).

read article

Novartis Reaches Another Regulatory Milestone For CTL019 (Tisagenlecleucel) With Submission Of Its MAA* To EMA For Children, Young Adults With r/r B-Cell ALL and Adult Patients With r/r DLBCL

(Novartis) Nov 6, 2017 - Novartis today announced that the company has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for CTL019 (tisagenlecleucel) for two indications.

read corporate press release

Novartis Seeks European Approval For Cell Therapy Kymriah

(Reuters) Nov 6, 2017 - Swiss drugmaker Novartis has submitted its cell therapy Kymriah for European approval in two forms of blood cancer, seeking to expand the use of a new treatment it hopes will eventually become a $1 billion-a-year seller.

read article
Next Page